Ordinance for the Manufacture of Medicinal Products and Active Pharmaceutical Ingredients (“Arzneimittel- und Wirkstoffherstellungsverordnung — AMWHV”, section 2, §10, §20)

The Ger­man Or­di­nan­ce for the Ma­nu­fac­tu­re of Me­di­ci­nal Pro­ducts and Ac­ti­ve Phar­maceu­ti­cal In­gre­dients is an or­di­nan­ce for the im­ple­men­ta­ti­on of the prac­ti­ce for pro­duct with hu­man ori­gin. It was is­sued by the Fe­deral Mi­nis­tries of He­alth and Food, Agri­cul­tu­re and Con­su­mer Pro­tec­tion in agree­ment with the Fe­deral Mi­nis­ters of Eco­no­mics, Tech­no­lo­gy and the En­vi­ron­ment and with the con­sent of the Bundesrat

Com­pu­ter-ba­sed sys­tem are dealt with in sec­tion 2, §10 of the Or­di­nan­ce for the Ma­nu­fac­tu­re of Me­di­ci­nal Pro­ducts and Ac­ti­ve Phar­maceu­ti­cal In­gre­dients. It spe­ci­fies that com­pa­nies and or­ga­niz­a­ti­ons have to main­tain a do­cu­men­ta­ti­on sys­tem in ac­cordance with the re­spec­ti­ve ac­ti­vi­ties per­for­med. The do­cu­men­ta­ti­on must be main­tai­ned clear­ly and wi­thout er­rors and must be up-to-date. If re­cords are kept with elec­tro­nic data pro­ces­sing sys­tems, the sys­tem must be suf­fi­ci­ent­ly va­li­da­ted. It is an un­der­ly­ing re­qui­re­ment to en­su­re that the in­for­ma­ti­on is avail­ab­le du­ring the en­t­i­re le­gal re­ten­ti­on pe­ri­od and can be pro­vi­ded in le­gi­ble form in a re­a­son­ab­le amount of time. The data must be pro­tec­ted against loss or da­ma­ge du­ring the en­t­i­re re­ten­ti­on pe­ri­od. The re­cords must be or­ga­ni­zed in a way al­lowing for an immedia­te re­call of the pro­duct. With re­gard to soft­ware, the pro­vi­der must the­re­fo­re en­su­re that it is avail­ab­le at all times and that the do­cu­men­ta­ti­on is al­ways accessible.

Fi­nal­ly, §20 “Sto­rage of the do­cu­men­ta­ti­on” (“Auf­be­wah­rung der Do­ku­men­ta­ti­on”) re­qui­res that any do­cu­ments may only be stored in rooms which are re­gar­ded as ade­qua­te and ap­pro­ved in the Or­di­nan­ce for the Ma­nu­fac­tu­re of Me­di­ci­nal Pro­ducts and Ac­ti­ve Phar­maceu­ti­cal In­gre­dients. The room ty­pi­cal­ly has to be lo­ca­ted on the company’s pre­mi­ses. For fur­ther de­tails on the con­tai­ned re­qui­re­ments, the Or­di­nan­ce for the Ma­nu­fac­tu­re of Me­di­ci­nal Pro­ducts and Ac­ti­ve Phar­maceu­ti­cal In­gre­dients re­fers to the EU-GMP guideline.

Your path to digitization — Discover our software

Our di­gi­ta­liz­a­ti­on so­lu­ti­ons pri­ma­ri­ly ad­dress do­cu­ment-ba­sed pro­ces­ses in ma­nu­fac­tu­ring, pro­duc­tion and qua­li­ty ma­nage­ment. The ba­sis of the d.3 life sci­en­ces sys­tem is a ho­listic ECM/DMS sys­tem. The ECM/DMS sys­tem can be lin­ked to your exis­ting ERP sys­tem (e.g. SAP), thus en­ab­ling you to im­ple­ment al­most all do­cu­ment-ba­sed pro­ces­ses in your company. 
Live insight into the GxP-compliant document management system by d.velop Life Sciences

Share now!

Share on email
Share on facebook
Share on linkedin
Share on twitter
Share on whatsapp

Learn more about

Preventive Actions

De­fi­ni­ti­on of the term („What are pre­ven­ti­ve ac­tions?“) The ISO 9000 de­scri­bes a pre­ven­ti­ve ac­tion as a “mea­su­re to eli­mi­na­te the cau­se of a detected